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OPEN
REVIEW
Blocking HIV-1 transmission in the female
reproductive tract: from microbicide development
to exploring local antiviral responses
Sahar G Eid1,2, Niamh E Mangan3, Paul J Hertzog3 and Johnson Mak1,2
The majority of new HIV-1 infections are transmitted sexually by penetrating the mucosal barrier to infect target cells.
The development of microbicides to restrain heterosexual HIV-1 transmission in the past two decades has proven to be a
challenging endeavor. Therefore, better understanding of the tissue environment in the female reproductive tract may assist in
the development of the next generation of microbicides to prevent HIV-1 transmission. In this review, we highlight the important
factors involved in the heterosexual transmission of HIV-1, provide an update on microbicides’ clinical trials, and discuss how
different delivery platforms and local immunity may empower the development of next generation of microbicide to block HIV-1
transmission in the female reproductive tract.
Clinical & Translational Immunology (2015) 4, e43; doi:10.1038/cti.2015.23; published online 9 October 2015
HIV-1/AIDS has been a public health priority for the past three
decades. In 2013, an estimated of 35 million people were living with
HIV/AIDS worldwide while women accounted for 16 million people,
which represent 46% of the HIV infected population.1 HIV-1 sexual
transmission remains the main mechanism for its spread worldwide.
The infection rates of HIV are higher in women than in men, and that
could be because of less selection bias and a more permissive
environment in the female reproductive tract.2 Because of gender
inequality, women (particularly in developing countries) have limited
power to implement HIV-1 prevention options. The reliance on the
male sexual partner in HIV prevention practices often make women
more susceptible to acquire the virus infection 5–7 years earlier and
eightfold higher than men.3 Finding an effective method to reduce
these high infection rates among women is vital to control HIV-1
epidemic.
To curb the new HIV-1 infections, extensive efforts have been made
to develop HIV prevention methods involving anti-retroviral drugs
(ARVs) and microbicides with varying mechanisms.4 Since 1987 there
has been substantial development of anti-retroviral therapies, whereas
a combination of anti-retrovirals are used to lower HIV-1 viremia to
undetectable levels (⩽50 copies/ml).5 Achievement of persistent
low-level viremia is dependent on drug adherence and compliance
with the medication dosing. Individuals failing to adhere to drug
regimen increased the probability of generation of drug-resistant
mutants and viral shedding in the genital compartment thus raising
the risk of new HIV-1 infection.6 Currently, the US Food and Drug
Administration has approved 25 anti-retroviral agents in the treatment
against HIV-1. These anti-retroviral agents can be categorized based
on their mechanism of action into (i) nucleoside analog reverse
transcriptase inhibitors (NRTIs), (ii) non-nucleoside reverse transcrip-
tase inhibitors (NNRTIs), (iii) protease inhibitors (PI), (iv) entry
inhibitors (such as CCR5 co-receptor antagonists and fusion
inhibitors) and (v) integrase strand transfer inhibitors. Timing the
start of an anti-retroviral therapy is vital in reducing HIV-1 transmis-
sion. It has been suggested that early treatment against HIV-1 may
expose the patients to the cytotoxic effect of the drugs (for example,
rash, renal and hepatic abnormalities),7,8 although some of these
concerns have subsided with improved understanding of the pharma-
cokinetics and pharmacodynamics of these anti-retroviral agents.
The potential development of drug resistance has also been a concern
when monotherapy was used in treatment. Amongst all limitations,
poor adherence is likely to be a major factor in the development of
drug resistance HIV.9
The updated guidelines (April 2015) for ﬁrst-line of anti-HIV
regimen often consist of two NRTIs in combination with either an
integrase strand transfer inhibitors, or a PI, or a NNRTI. Patients
failing with the ﬁrst-line anti-retrovirals regimen will often be given an
alternative of either a NNRTI-based regimen, or a PI-based regimen,
or an integrase strand transfer inhibitors-based regimen, or all
combined. The choice of drugs to be included in the second-line of
anti-retroviral regimen is based on the patient’s treatment history, and
drug-resistance testing.10 The burden of the HIV/AIDS related disease
has been greatest in the poorest countries where the switch to the
second-line ARV regimen is not always an option because of:
high cost, inaccessibility to the drugs, and inadequate health care
infrastructures.11 The implementation of the aforementioned ARVs
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regimen often provides an undetectable viral load and lower transmis-
sion rate. Although combinational ARV treatment is unable to remove
the last trace of HIV-1 virus from the infected patient, loweing the cost
of ARVs and making them universally accessible would signiﬁcantly
impair the spread of HIV in a global scale. In the last two decades,
development of microbicides has emerged to be an alternative strategy
to reduce the incidence of new HIV infection.
In this review, we will discuss the unique relationship between
HIV-1, type-I interferons (IFNs) and mucosal immunity. In addition,
we will discuss the recent advances in microbicides development, and
the lessons learnt from these experiences for future design and
generation of effective microbicides against HIV.
MICROBICIDES PAST AND CURRENT CHALLENGES
Microbicides, by deﬁnition, act as a barrier and prevent acquisition of
HIV-1 via sexual transmission. Microbicides can roughly be divided
into two groups: (1) the non-anti-retroviral candidate microbicides;
and (2) the anti-retroviral based candidate microbicides. These two
groups of microbicides are sometimes grouped as ‘ﬁrst generation’ and
‘second generation’ of microbicide, respectively.12 One of the latest
microbicide developments consists of combination of anti-retroviral
agents with distinct mechanisms of action against HIV-1 in an attempt
to achieve greater level of protection. There is also strong inclination
to combine non-hormonal contraceptives with the candidate micro-
bicides as a preventive measure against HIV-1 transmission and
unwanted pregnancy.
A number of advances have been made to deliver microbicide
candidates into the female reproductive tract. These delivery systems
can be divided into coitally dependent (gels, ﬁlms, tablets and
diaphragms) and coitally independent (rings and ﬁbers) means.
Ideally, delivery of microbicides should not cause disruption to the
vaginal epithelium and to the innate microﬂora (complex vaginal
microbiome), as this might induce adverse effects. For example,
alteration of microﬂora proﬁles was reported in clinical trials upon
usage of 1% Tenofovir gel, whereas 3% of participants developed
asymptomatic vaginal candidiasis and sometimes bacterial vaginosis.13
As the association of bacterial vaginosis and high risk of HIV-1
transmission/susceptibility has been conﬁrmed,14,15 Pyles et al.16
highlighted the importance of screening vaginally applied compounds
(including microbicides), for impact on vaginal microbiome, using
colonized epithelial multilayer cultures method to detect unwanted
alterations in bacterial community proﬁles.16 Other considerations
include the timing of the product application and menses, as they are
imperative to maintain the effective dosage of microbicide needed to
block the transmission of HIV-1 and success in protection. In
addition, sustaining vaginal pH (pH⩽ 4.5) level, mainly via the
presence of L-lactic acid, is a critical determinant to having a broad-
spectrum HIV virucidal activity.17 Ultimately, an effective microbicide
against HIV-1 should offer protection against HIV-1 without com-
promising the existing delicate balance in the female reproductive tract
to prevent pathogen invasions.
NON-ANTI-RETROVIRAL BASED MICROBICIDE CANDIDATES
Only a small number of candidate microbicides have successfully gone
through the preclinical pipeline (high efﬁcacy and minimal toxicity,
both in vitro and in animal models) to clinical trial testing in humans.
First-generation microbicides include surfactants, blockers and buffers
(Table 1). Among the surfactants group, two products (nonoxynol-9
and C31G) were clinically investigated. They act by disrupting the viral
envelopes (solubilizing lipids or denaturing proteins). Nonoxynol-9
(N-9) is a known spermicide that went through clinical trials between
1992–2002 based on different formulations (gel, vaginal ﬁlm and
Table 1 First- and second-generation microbicides clinical trials summary (modiﬁed from Cottrell and Kashuba12 and D'cruz and Uckun108)
Candidate microbicide Category Formulation
Clinical trial
phase Outcome
Nonoxynol-9 Surfactant 1000mg Sponge gel II No success and vaginal epithelial disruption
70mg Film II No success and 30% increase of vaginal irritation
3.5% Gel II/III Failed; higher rate of HIV acquisition associated with frequency of use
plus epithelial disruption
C31G (SAVVY) Surfactant 1% Gel III Failed (early termination) in preventing HIV and was associated with
genital irritations
Carraguard (sulfate
polysaccharide)
Blocker 3% Gel II Failed to provide protection against HIV
Celllose sulfate Blocker 6% Gel III Failed to provide protection against HIV and possible harm
PRO2000 Blocker 0.5–2% Gel IIb/III No statistical difference and uselessness in preventing HIV
BufferGel (polyacrylic
acid)
Buffer Gel IIb No statistical difference with trend toward increase in HIV incidence
Tenofovir (TFV) HIV replication inhibitor
(NtRTI)
1% Gel II (CAPRISA
004)
39% reduction of HIV acquisition to 54% in high adherer’s women
TDF HIV replication inhibitor
(NtRTI)
1% Gel III (VOICE) Failed to show efﬁcacy in preventing HIV
Stampidine HIV replication inhibitor
(NRTI)
5–25mg kg−1 Capsule I Clinically safe; no toxicity
Dapivirine HIV replication inhibitor
(NNRTI)
Intravaginal ring (IVR 25mg or
IVR 200mg)
I Considered safe and tolerated by prticipants
Dapivirine+Maraviroc NNRTI+CCR5
antagonist
IVR (25 +100mg) I Completed but results have not been published yet
GSK’744 Integrase strand-
inhibitor
Monthly injection I Tolerated by the participants
Abbreviations: NtRTI, nucleotide reverse transcriptase inhibitor; TDF, TFV-disoproxil fumarate.
Blocking HIV-1 transmission Plby microbicides and ARVs
SG Eid et al
2
Clinical & Translational Immunology
suppositories). The clinical trials showed an inverse association
between HIV-1 incidence and frequency of suppository use; whereas
an increase of the administered dose to twice and four times daily has
led to epithelial disruption.18 The N-9 vaginal ﬁlm formula showed no
beneﬁt but possible harm, and 30% increase of vaginal irritation.19
Two studies using the gel formulation (COL-1492) demonstrated a
higher rate of HIV-1 acquisition and positively associated with
frequency of use, plus epithelial disruption.20 Like N-9, C31G
(SAVVY) showed disappointing results (studied in four trials for
safety evaluation and two trials for effectiveness between 2004 and
2008) in preventing HIV-1 transmission, and was associated with
genital irritations.21,22 The next class of candidate microbicides
assessed was the ‘blockers’ (cellulose sulfate gel, Carraguard and
PRO 2000). They act by interfering with HIV-1 attachment to the
host cells. The ﬁrst product assessed was Carraguard (sulfate poly-
saccharide derived from seaweed). Perotti et al.23 showed effectiveness
of carrageenan in blocking HIV-1 infection of cervical epithelial cells
and preventing macrophages trafﬁcking from the vagina to lymph
nodes. Although Carraguard (gel) was safe, it failed to provide
protection against HIV-1 in the efﬁcacy trial24 (Table 1). The second
‘blocker’ investigated was cellulose sulfate (vaginal gel). Two phase III
clinical trials of 6% cellulose sulfate gel showed ineffectiveness in
preventing HIV-1 infection.25,26 Later on, Mesquita et al.27 showed
that disruption of epithelial cells tight junctions by cellulose sulfate
reduced epithelial barrier and activated proinﬂammatory signaling
pathway, thus facilitating HIV-1 infection. The last product in this
category is PRO 2000 vaginal gel (naphthalene sulfonate). PRO 2000
vaginal gel was evaluated in two trials and proven ineffective in
preventing HIV infection in women.28,29
In the category of ‘Buffers’, the last in the ﬁrst-generation
microbicides, BufferGel (polyacrylic acid) was checked in efﬁcacy trial
and demonstrated no beneﬁt in protection against HIV-128 (Table 1).
The underlined principle for this category of microbicide is to preserve
the acidic/low pH of the vaginal milieu that can be elevated by the
presence of semen or reduction of lactobacilli (vaginal ﬂora bacteria).
As an alternative to the abovementioned non-anti-retroviral
candidates, LACTIN-V (Lactobacuillus crispatus) and a live recombi-
nant Lactobacillus jensenii (producing cyanovirin-N lectin which has
high afﬁnity recognition of gp120 carbohydrate moieties) was shown
to be safe, tolerated among women, reduced SIV (63%) in animal
trials and may proceed in the microbicides development pipeline.30,31
ANTI-RETROVIRAL BASED MICOBICIDE CANDIDATE
Anti-retroviral based microbicide candidates comprise HIV replication
inhibitors (Tenofovir, Dapivirine, and Stampidine), HIV fusion
inhibitors (Maraviroc) and HIV integrase inhibitor (GSK’744), which
were evaluated in clinical trials, in addition to promising candidates in
preclinical studies (MIV-150, HI-443, Rilpivirine and PSC-RANTES).
Tenofovir (TFV) is a Food and Drug Administration-approved drug
for HIV-1 treatment. TFV is a nucleotide reverse transcriptase
inhibitor (NtRTI), and it blocks the synthesis of viral cDNA during
infection. TFV was formulated as a vaginal gel by containing the TFV
or TFV- disoproxil fumarate (TDF) (Table 1). Application of TFV gel
(1%) before and after sex was included in a phase II clinical trial
(CAPRISA 004). The CAPRISA 004 trial showed 39% reduction of
HIV-1 acquisition but two seroconverters were super-infected with
HIV subtype C.32 However, HIV-1 incidence was reduced to 54% in
high adherer’ women.32
The VOICE trial (phase IIb) dealt with evaluation of daily dosage of
1% TDF gel, oral TDF and TFV+FTC (entricitabine) or Truvada. The
VOICE trial failed to show efﬁcacy in preventing HIV-1 transmission
in women.33 It is thought that the lack of protection against HIV-1
was attributed to low adherence of the participants. In addition, a
number of ongoing trials will provide invaluable insight for the future
development of this microbicide. For example, FACTS 001 (phase III)
is a trial that has been completed in April 2015. This study will reveal
the effectiveness of TDF gel in preventing the transmission of HIV-1
and HSV-2,34 whereas CAPRISA 009 trial was recently completed in
April 2015, and will determine whether exposure to TFV gel alters the
therapeutic responses to future TFV containing ARVs regimen.35
Other ongoing trial, such as CAPRISA 008 (phase III), is the
continuation of CAPRISA 004 trial. It is aimed to assess the
effectiveness and safety of TFV gel provision through family planning
services.36 Recently, two safety studies have been completed by
investigating the effect of tenofovir gel (1%) application on pregnancy
and lactation (MTN-008), plus the effect of contraception and
menstrual cycle on the gel use and effectiveness in protection
(A10–114).37,38
Volk et al.39 provided analyses on data collected between July 2013
and February 2015 from pre-exposure prophylaxis—PrEP (tenofovir/
enticitabine) initiators and non-initiators among members of the
Kaiser Permanente Medical Center in San Francisco. The authors
observed high rates of sexually transmitted infection (STIs) (50%)
after 12 months use of PrEP. However, there was no HIV diagnosis
among PrEP initiators and was associated with 41% decrease in the
reported use of condoms. Despite the limitation of this study, the
authors’ recommendations were to increase understanding of ‘risk
compensation’ and how sexual risk behavior may impact PrEP users,39
In addition, the risks from prolonged exposure to ARV-based
microbicide candidates, such as kidney toxicity, mitochondrial toxi-
city, osteoporosis and emergence of drug resistance HIV-1 mutants
because of poor adherence, still require more attention and careful
evaluation. However, a number of barriers and challenges remain
including behavioral disinhibition/risk compensation, societal stigma-
tization against HIV and healthy individuals’ reluctance of using anti-
HIV-1 drug as preventive strategy. Recently, Biswas et al.40 assessed the
effect of TFV on epithelial cells, ﬁbroblasts, CD4+ T-cells and CD14+
cells isolated from the female reproductive tract (endometrium,
endocervix and ectocervix). They found that TFV induces proinﬂam-
matory responses in the female reproductive tract (site-speciﬁc) by
upregulating Interleukin (IL)-8, tumor necrosis factor alpha (TNF-α)
and macrophage inﬂammatory protein 3α (MIP-3α), which may
potentially increase the risk of HIV-1 acquisition. Adding up, TFV
modulation of proinﬂammatory cytokines (TNF-α, IL-2, IL-7, and
IL-12p70) and activation of natural killer cells were associated with
HIV-1 acquisition in women showing high systemic innate immune
activation before infection.41
Aside from TFV, a distinct new HIV anti-retroviral, stampidine, was
evaluated recently in phase I clinical trial, and showed no toxicity at
dosage ranging from 5 to 25mg kg− 1 when taken daily as capsules,42
which offers an alternative option of using anti-retrovirals as micro-
bicide strategy. To overcome barriers to adherence, intravaginal ring
(IVR 25mg or IVR 200mg) formulated with a non-nucleoside
RT inhibitor (Dapivirine) has been developed. Intravaginal ring was
demonstrated to be safe and tolerated in phase I trials (Table 1),43,44
which is likely to help maintain adherence for future clinical
application.
Several anti-retroviral agents (for example, NNRTIs: MIV-150,
Rilpivirine and HI-443; CCR5 antagonist: PSC-RANTES) are being
considered as potential candidate microbicides. These compounds
have good records in preclinical studies and are being considered for
different formulations for delivery. One of the current focuses is on
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the development of combination microbicides targeting different steps
in the HIV-1 life cycle in parallel with improving the efﬁcacy of the
delivery systems (for example, gels, rings). Lehman et al.45 have
showed that selected drug resistance mutations can be detected in
patients who acquired HIV-1 after participating in microbicide clinical
trials. Drug resistance remains a major concern when ARV is being
used as part of the microbicide strategy. Furthermore, the rise of the
drug-resistant virus transmission (5–15%) in areas where ARVs have
been used for long period of time is an important public health
concern,46 which can negatively impact on the effectiveness of
ARV-based microbicides. In addition, the lack of comprehensive
knowledge of the long-term effects of these ARV based microbicides
on the female reproductive tract (such as vaginal cells and tissues,
epithelial integrity, inﬂammatory responses and vaginal microbiota) is
also a concern. It is therefore important to consider an alternative
strategy to develop a non-ARV-based microbicide to empower the
natural host defenses within the female reproductive tract to prevent
HIV-1 infection.
FEMALE REPRODUCTIVE TRACT IMMUNOBIOLOGY AND HIV-1
HETEROSEXUAL TRANSMISSION
Understanding the female genital tract immunobiology is important in
designing any preventive methods to HIV-1 spread. The female
reproductive tract represents a unique site where a balance must be
maintained to ensure successful pregnancy and at the same time to
offer protection against sexually transmitted diseases. The female
reproductive tract consists of two different types of mucosal surface:
type I mucosa (endocervix, endometrium, and the fallopian tubes) and
type II mucosa (vagina and ectocervix). Type I mucosal surface
includes a monolayer of columnar epithelial cells with tight junction
contrary to type II mucosal surface, which is covered with multilayer
of squamous epithelial cells47 (Figure 1). It is well known that the
multilayer of squamous epithelial cells and the tight junctions between
columnar epithelial cells present good barrier protection in upper and
lower female reproductive tract. The transition between the squamous
and columnar epithelial cells occurs at the cervical transformation
zone (Figure 1) and it is believed to provide a more susceptibility
site for HIV-1 penetration and transmission. However, the actual
anatomical site(s) of initial HIV-1 infection establishment is still highly
debated. It was demonstrated that hysterectomized women (lacking a
cervix) and hysterectomized macaques (lacking a cervix) can be
infected with HIV-I and SIV (simian immunodeﬁciency virus),
respectively, by crossing the vaginal mucosa.48,49 This could be
explained either by infection of mucosa cells (epithelial cells) or that
the virus can cross an intact mucosal barrier. Micsenyi et al.50 reported
infection of epithelial cells with HIV-1 leading to de novo infection of
underlying CD4+ T-cells in a contact-dependent manner. On the
other hand, SIV infection of macaques showed that the virus can cross
intact mucosal barrier, and infect intraepithelial Langerhans cells, that
can extend through epithelial cells into the vaginal lumen.51 In
addition, resident immature dendritic cells (DC) can trap HIV-1
through C-type lectin DC-SIGN, and migrate to secondary lymphoid
tissue and undergo maturation where they can subsequently infect
neighboring CD4+ T-cells via trans-infection.52 Recently, it was shown
that trans-infection is strongly enhanced via sialic acid binding
Immunoglobulin-like lectin 1 (Siglec-1), which is a type-I interferon
(IFN) inducible gene product, and highly expressed on mature
DC.53,54 This data shows that, while many IFN-stimulated genes
(ISGs) are expressed in the early stages of HIV infection to suppress
viral infection,55,56 HIV-1 has evolved ways to recruit host
IFN-induced genes to help establish infection In vivo.
It is well known that the vaginal submucosa area is heavily
populated with a spectrum of HIV-1 target immune cells including
mainly CD4+ T-lymphocytes cells, antigen-presenting cells
(DC and Langerhans cells), natural killer cells, neutrophils and
macrophages.57,58 Therefore, understanding the biological impacts of
candidate microbicides on this target population of immune cells is
crucial for the development of an effective microbicide formulation.
Whether cell-free or cell-associated HIV-1 virus particles are
responsible of initiating infection; HIV-1 heterosexual transmission
is initiated by a presumably ﬁtter genetic variant (founder virus) in the
vaginal mucosal compartment.2 Founder virus requires cell surface
receptors (CD4) and co-receptors (CCR5 rather than CXCR4) for
attachment and entry. Infection will eventually expand locally then
spread via lymphatic drainage to establish in the draining lymph
nodes. Shortly thereafter, HIV-1 viral RNA is detected in the
circulation around 21–28 days after sexual mucosal exposure at which
time mucosal (for example, genitorectal and gastrointestinal tracts)
CD4+ T-cells undergo severe depletion related to viral cytopathogeni-
city and failing of CD4+ memory T-cell homeostasis.59 This depletion
of T-cells can be restored slowly or incompletely under combined
anti-retroviral therapy.60,61 In addition, increased risk of HIV-1
transmission has been found to be associated with sexually transmitted
infections including herpes simplex type-2,62 bacterial vaginosis,15
pregnancy,63 as well as hormonal contraception options.64–66
HOW SEX HORMONES AND HIV-1 WINDOW OF
VULNERABILITY ARE RELATED
The host cell responses in the female reproductive tract are affected by
sex hormones and the continuous variation of the ratio between the
levels of progesterone and those of estrogen. It has been suggested that
a ‘window of vulnerability’ of HIV-1 infection coincides with the high
levels of progesterone in the secretory phase.67 This vulnerability may
be due to thinning of the vaginal epithelium during the secretory
phase resulting in increased susceptibility to HIV-1 by reaching
the underlying target immune cells as showed in macaque
experiments.68–70 Others have demonstrated increased frequency of
CCR5+CD4+ T-cells (HIV-I target cells) and α4β7 expression on DCs
(its expression inﬂuences preferential trafﬁcking to gut lamina propria
and associated lymphoid tissues) in the vaginal tissue and endocervix
tissue respectively in progesterone treated macaques.71
On the other hand, the female reproductive tract epithelial cells act
as a barrier and contribute to protection by secreting factors that
display potent antimicrobial activity (that is, HD5, HBD1–4, Elaﬁn,
and SLP1), chemokines/cytokines (that is, IL-8, CCL20, RANTES).72
More recently, a novel cytokine IFN-epsilon (IFN-ɛ) with potent
antimicrobial activity has been shown to be expressed in the luminal
and glandular epithelial cells of the endometrium.73 However, these
factors are also regulated by sex hormones and dependent on the
anatomic site within the female reproductive tract. Therefore, it is
important to study the anti-HIV-1 activity of candidate microbicides
throughout the menstrual cycle.
HIV-1 TRANSMISSION—CYTOKINES AND ROLES OF
TYPE-I IFNS
Exposure to HIV-1 and activation of innate immunity can result in
rapid upregulation and release of cytokines, chemokines and chemo-
kine receptors leading to recruitment of additional DCs and T-cells. In
addition, epithelial cells, ﬁbroblasts and immune cells in the female
reproductive tract contribute to this pool of cytokines and chemokines
through an autocrine or paracrine loop. For instance, epithelial cells
secrete proinﬂammatory cytokines (IL-6, IL-8 and MIF), IFN-β,
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defensins (antimicrobial peptides) and MIP3-α/CCL20 (recruits
CCR6+ plasmacytoid DCs), whereas resident macrophages and DCs
secrete antiviral factors such as type-I IFNs and cytokines.74
Furthermore, migrating cells were shown to secrete IFN-α, IFN-β,
MIP-1α, MIP-1β, and CCL5 or RANTES (CCR5+ chemoattractant
chemokines), which recruit additional HIV-1 target cells and partici-
pate in expanding the infection.75 HIV-1 founder viruses have been
shown to be less sensitive to IFN-α76,77 thus avoiding this cytokine
storm, despite a high level production of IFN-α by plasmacytoid DCs,
by counteracting IRF-3 and modulating NF-κB, thus disrupting the
innate signaling pathways in infected cells.78,79
IFN-α THROUGHOUT THE COURSE OF HIV-I DISEASE
IFN-α is produced and secreted following cellular detection of
pathogen-associated molecular patterns by pattern-recognition
receptors to pilot the upregulation of ISGs.80 ISGs that exhibit
restriction to HIV-1 infection will be brieﬂy introduced here by order
of their obstruction with HIV-1 life cycle from entry to de novo virions
production and the correspondent antagonist HIV-1 proteins
(Figure 1).
Shortly after HIV-1 entry, the virus encounters the tripartite motif
(TRIM) protein TRIM5α that binds to the virus capsid and
presumably accelerates the disassembly of the virus capsid structure
before reverse transcription can occur. Therefore, it is thought that
TRIM5α block HIV infection via dismantling the virus, although the
exact mechanism is still unclear.81 Another protein of the same family
TRIM22 was found to inhibit HIV-1 Gag protein trafﬁcking to host
cell membrane. TRIM22 interferes in the very last stage of the virus life
cycle and decreases virus particle production.82 After virus entry and
uncoating, apoliprotein B-editing catalytic polypeptide-3G protein,
APOBEC3G, exerts its antiviral activity during reverse transcription
by driving hypermutation in the newly synthesized viral cDNA, or
reducing priming and initiation of viral cDNA synthesis. As a result,
this hypermutation fate leads to degradation by a cellular DNA repair
mechanism yielding proviruses that are non-functional.83,84 HIV-1
counteracts APOBEC3G restriction by the viral infectivity factor (Vif).
Figure 1 Schematic representation of the human female reproductive tract mucosa surveyed by innate and adaptive immune cells and antiviral responses
(generated using ePath3D: http://www.epath3d.com). First part: type I mucosa, type II mucosa, transformation zone and spectrum of resident immune cells.
Second part: secretion of IFNα by dendritic cells occurs upon infection while IFNɛ by epithelial cells is constitutively expressed and hormonally regulated.
Target stages of IFNα-Stimulated genes within HIV-1 life cycle: Red connectors with round head represent inhibition of particular stage of HIV-1 life cycle by
the designated cellular restriction factor(s) and the green hexagons represent the viral counterpartners. Question marks (?) represent unresolved questions.
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Vif induces proteasomal degradation of APOBEC3G and blocks its
catalytic activity. In addition, Vif reduces APOBEC3G translation and
packaging into the viral particle, which ultimately lessen the APO-
BEC3G mediated antiviral effect.85,86 The next step in the HIV-1 life
cycle is the transportation of the synthesized double-stranded viral
cDNA into the cell nucleus. It has been suggested that the murine
myxovirus resistance 2 (Mx2) can act at the level of nuclear entry and
ultimately obstruct chromosomal integration of the viral cDNA.87
Other ISG products that may impair retrovirus infection include
SAMHD1. The cytoplasm and nucleus localized sterile alpha motif and
histidine-aspartate domain containing protein 1 (SAMHD1) reduces
the intracellular nucleotide pools and consequently affects retrovirus
reverse transcription and replication. SAMHD1 is expressed in
monocytes, macrophages, DCs, and resting CD4+ T-cells.88–90
SAMHD1 has a greater antiviral activity against both HIV-2 and
SIV over HIV-1.91 No anti-SAMHD1 counteracting protein has yet
discovered in HIV-1 infected cells and it seems that HIV-1 can tolerate
lower levels of nucleotides available in macrophage during cDNA
synthesis owing to the enzyme kinetics of HIV-1 RT to support viral
replication in low concentrations of substrates.92 At the late stage of
HIV-1 replication cycle, the release of virus particles is barred by the
type 2 transmembrane protein ‘Tetherin’ through physical binding
and trapping of HIV-1 particles on the plasma membrane.93 Tetherin
is constitutively expressed in B cells and plasmacytoid DCs.94
Antagonizing Tetherin function by HIV-1 Viral protein unique
(Vpu) includes ubiquitination followed by Tetherin degradation.95
Another ISG protein that have been shown to have anti-HIV-1
activity is Viperin. It is thought that Viperin block HIV infection via
inhibiting farnesyl diphosphate synthase, which alters the plasma
membrane ﬂuidity and thus particles’ release.96
Despite the available of large number of ISGs to suppress HIV-1
infection, once HIV-1 transmission has occurred and infection is
established in the host, type-I IFN sensitivity itself is unable to stop the
spread of HIV-1 amongst different compartments of the infected
host.97,98 In vivo studies have been conducted to assess the impacts
of interferon administration on the spread of retrovirus infection
and progress of the disease. Treatment of macaques with pegylated
IFN-α2a during SIV challenge increased host resistance to systemic
infection, despite the evidence suggesting that inﬂammation intensiﬁes
virus acquisition and disease progression.97Although once SIV infec-
tion is established in the host, continued pegylated IFN-α2a treatment
resulted in a decrease of antiviral gene expression, which increases the
susceptibility to the spread of infection and greater CD4+ T-cell
depletion compared to placebo,97 and a similar conclusion was
depicted by Asmuth et al.98 when chronically SIV-infected macaques
were injected with pegylated IFN-α2a. Sandler et al.97 highlighted the
importance of timing and duration of type-I IFN administration in
shaping the course of the disease development. More speciﬁcally, early
type-I IFN signaling was critical for early and long-term control of SIV
replication and virus reservoir in macaques. At the same time, a delay
of as few as 3 days in antiviral gene expression after SIV infection is
established can result in accelerated disease progression.97 Accordingly,
type-I IFN treatment requires different therapeutic strategies at each
stage of the course of HIV-1 disease.
IFN-ɛ ROLE IN FEMALE REPRODUCTIVE TRACT
IFN-ɛ, a novel type-I IFN, was identiﬁed in humans (chromosome
9p21) and mice (chromosome 4).99 IFN-ɛ was found to be located
within type-I IFN locus as a single copy. It comprises conserved
progesterone receptor binding site in the proximal promoter but
interestingly the response elements for pattern-recognition receptors
are limited as opposed to other type-I IFN.73,99 IFN-ɛ shares only 30%
amino acid homology to consensus IFN-α and to IFN-β. Based on
coding sequence, IFN-ɛ is most closely related to IFN-β. Human
IFN-ɛ is 15 residues longer than mouse IFN-ɛ and they share 54%
amino acid identity and 15% amino acid similarity.99 The predicted
structures of IFN-ɛ have overall similarity to the type-I IFN and it was
conﬁrmed later on by the ability to bind to the type-I IFN receptor
complex.73,99 Contrary to other classical type-I IFN, IFN-ɛ is not
induced by pattern-recognition receptors pathways, IFN-ɛ is expressed
constitutively by epithelial cells of the female reproductive tract and its
expression level is regulated by sex hormones. The detectable levels of
IFN-ɛ expression are highest in the proliferative stage (estrogen
dominant) and lower in secretory phase (progesterone dominant) of
the menstrual cycle.73 The expression level of IFN-ɛ (with potential
antimicrobial activity) concurs with the ‘window of vulnerability for
HIV-1’ when the conditions are optimized for fertilization and
pregnancy. Fung et al.73 revealed the protective role of IFN-ɛ in the
female reproductive tract by maintaining basal levels of ISGs (2’5’oas,
Irf-7, Isg15) in the murine model. IFN-ɛ-deﬁcient mice, challenged
with genital HSV-2 or Chlamydia muridarum infection, showed
increased susceptibility to infection compared to wild-type mice.
There was no change in the expression of Ifn-ɛ in wild-type mice,
as it is not pathogen induced, and protection was granted by activating
recruitment of natural killer cells.73 The quite distinct role and
importance of IFN-ɛ in mucosal immunity was the focal point in
different studies but still the mechanism is not fully understood. It is
intriguing to evaluate IFN-ɛ in HIV-1 heterosexual transmission
(Figure 1), which raises the question of how IFN-ɛ may protect the
female reproductive tract from HIV-1 infection. Which HIV-1-related
restriction factors are favorably induced by IFN-ɛ? What immune cell
types are activated? Does IFN-ɛ support trans-infection mechanism
from DCs to target cells? Could it be considered as a candidate
microbicide?
CONSIDERATIONS FOR PROSPECTIVE CANDIDATE
MICROBICIDE
Finding safe and effective non-ARV-based anti-HIV-1 microbicides,
delivered efﬁciently and accepted by users, would provide new venues
for the control of the HIV/AIDS epidemic. Candidate microbicide that
progress in the production pipeline will be tested in vitro, ex vivo
(vaginal mucosal explants, female reproductive tract immune cells,
microﬂora) and in vivo on animal models (bone/liver/thymus mice,
and non-human primates), despite the fact that impressive preclinical
data are not always predictive of the success of such microbicides
formulation to prevent HIV infection in humans. However, studying
the effects of candidate microbicides throughout the menstrual
cycle on vaginal cells and tissues (ﬁrst cells to encounter HIV-1
in heterosexual transmission), epithelial integrity, inﬂammatory
responses and vaginal microbiota is becoming a prerequisite. In
addition, it is important to test the efﬁcacy of candidate microbicides
in the presence of semen as shown by Ziraﬁ et al.100 where there was
an enhancement of HIV-1 infectivity in presence of semen resulting in
the impaired antiviral activity of most candidate microbicides except
maraviroc (CCR5 antagonist).100 It is thought that the amyloid ﬁbrils
in semen enhance HIV infectivity by promoting viral attachment to
the target cells.101,102 A mutually non-exclusive explanation would be
the induction of proinﬂammatory cytokines (IL-6 and IL-1β),
chemokines (IL-8 and MCP-1), and IL-7 by seminal plasma that
facilitate HIV infection In vivo.103–105
IFN-ɛ has a unique role at the mucosae immunity and the
probability of considering it as future candidate microbicide is
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dependent on many factors. IFN-ɛ (i) is not induced by PPR as seen
with other type-I IFNs, (ii) endogenous IFN-ɛ is well tolerated as it is
expressed constitutively by epithelial cells in the female reproductive
tract where levels are hormonally regulated, (iii) is known to provide
protection against common sexual transmitted infections in mice
(HSV-2 and Chlamydia), (iv) is not suppressed by seminal ﬂuids for
its expression, (v) is induced by human ectocervical epithelial cells
following exposure to seminal ﬂuid, (vi) is required to maintain basal
levels of ISGs in the female reproductive tract, (vii) is activated to
facilitate recruitment of natural killer cells, (viii) is exclusively
expressed by epithelial cells of mucosal tissues in Indian rhesus
macaques (can be used for preclinical studies) and (ix) is important
to enhance lymphocytes recruitment (cytotoxic CD8+CD4+ T-cells
subset in lymph nodes but not memory CD8+ T-cells responses), and
to promote migration of antigen-speciﬁc CD8+ T-cells to the gut
mucosae, and reduced inﬂammation.73,103,106,107 Together, these
features highlight the antiviral potential of this naturally produced
cytokine IFN-ɛ, which may offer unique protection against HIV-1 in
the female reproductive tract.
The anti-HIV mechanisms of type-I IFNs have most impact at the
acute stage of infection, but they are ‘too late’ and ‘less efﬁcient’ to
suppress HIV-1 replication once infection is ﬁrmly established within
the host. IFN-ɛ provides a new modality of immune protection of the
female reproductive tract in comparison with other type-I IFNs. These
initial results of IFN-ɛ contribution to mucosal immunity ﬁt with the
principal mechanisms of HIV-1 protection. It would be very impor-
tant to study the effect of exogenous application of IFN-ɛ throughout
the menstrual cycle on the epithelial cells (tight junctions), the
immune cells population in the female reproductive tract, fertilization,
pregnancy and fetus.
The key question is whether IFN-ɛ is able to elicit protective
immune responses without fueling immune activation to support
HIV-1 replication in vivo; whereas detection of a proinﬂammatory
signature will be a major criterion. Investigating the effect of IFN-ε on
the residing immune cells will give an insight on its relevance in
antiviral protection. Some of the focal points will be around its effect
on DCs as they are the most potent antigen-presenting cells and the
connection between the innate and adaptive immune systems. In
addition, scrutinizing the induced ISGs and their antiviral activity will
be central to understand IFN-ε protective mechanism. Despite the fact
that IFN-ɛ is an endogenous protein, side effects may occur and this
demands caution in timing and dosages. IFN-ɛ could be considered
for different formulations for delivery as vaginal gel or intravaginal
ring, plus the ability to combine it with other candidate microbicides
may add a boost protection. The big challenge would be identifying
the exact set of effector molecules induced by IFN-ɛ at the vaginal
mucosa and their roles in protection against heterosexual transmission
of HIV-1. The answers to these questions may hold the key for the
development of the next generation of microbicide to offer greater
protection against HIV-1 and/or other sexual transmitted diseases via
the female reproductive tract.
CONCLUDING REMARKS
Although none of the candidate microbicides has progressed for
clinical application currently, the innovation in microbicide’s formu-
lations and advancement in preclinical and clinical trials have already
paved the way for more rapid development of future microbicides.
Understanding the female reproductive tract immunobiology, and the
transmission of HIV-1, is a prerequisite in the quest of ﬁnding a safe
and effective candidate microbicide to prevent HIV-1 acquisition.
Candidate microbicides offering novel and promising prevention
modality should be investigated in depth. Better knowledge will lead
to improved approaches to prevent HIV-1 transmission and address
important issues in women’s sexual and reproductive health needs.
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